keyword
https://read.qxmd.com/read/38576816/latest-updates-on-structure-and-recommendations-of-cardiac-rehabilitation-programs-in-chronic-heart-failure
#21
EDITORIAL
Christos Kourek, Alexandros Briasoulis, Dimitrios E Magouliotis, John Skoularigis, Andrew Xanthopoulos
Chronic heart failure (HF) is a clinical syndrome with high morbidity and mortality worldwide. Cardiac rehabilitation (CR) is a medically supervised program designed to maintain or improve cardiovascular health of people living with HF, recommended by both American and European guidelines. A CR program consists of a multispecialty group including physicians, nurses, physiotherapists, trainers, nutritionists, and psychologists with the common purpose of improving functional capacity and quality of life of chronic HF patients...
March 16, 2024: World Journal of Clinical Cases
https://read.qxmd.com/read/38576652/cardiac-mri-an-overview-of-physical-principles-with-highlights-of-clinical-applications-and-technological-advancements
#22
REVIEW
Mason T Stoltzfus, Matthew D Capodarco, Fnu Anamika, Vasu Gupta, Rohit Jain
The purpose of this review is to serve as a concise learning tool for clinicians interested in quickly learning more about cardiac magnetic resonance imaging (CMR) and its physical principles. There is heavy coverage of the basic physical fundamentals of CMR as well as updates on the history, clinical indications, cost-effectiveness, role of artificial intelligence in CMR, and examples of common late gadolinium enhancement (LGE) patterns. This literature review was performed by searching the PubMed database for the most up-to-date literature regarding these topics...
March 2024: Curēus
https://read.qxmd.com/read/38570258/2024-australia-new-zealand-expert-consensus-statement-on-cardiac-amyloidosis
#23
JOURNAL ARTICLE
Nicole K Bart, Diane Fatkin, James Gunton, James L Hare, Dariusz Korczyk, Fiona Kwok, Kaitlyn Lam, David Russell, Hasib Sidiqi, Tim Sutton, Simon D J Gibbs, Peter Mollee, Liza Thomas
Over the past 5 years, early diagnosis of and new treatments for cardiac amyloidosis (CA) have emerged that hold promise for early intervention. These include non-invasive diagnostic tests and disease modifying therapies. Recently, CA has been one of the first types of cardiomyopathy to be treated with gene editing techniques. Although these therapies are not yet widely available to patients in Australia and New Zealand, this may change in the near future. Given the rapid pace with which this field is evolving, it is important to view these advances within the Australian and New Zealand context...
April 2, 2024: Heart, Lung & Circulation
https://read.qxmd.com/read/38551786/worth-their-weight-an-update-on-new-and-emerging-pharmacologic-agents-for-obesity-and-their-potential-role-for-persons-with-cardiac-conditions
#24
REVIEW
Josephine Harrington, G Michael Felker, James L Januzzi, Carolyn S P Lam, Ildiko Lingvay, Neha J Pagidipati, Naveed Sattar, Harriette G C Van Spall, Subodh Verma, Darren K McGuire
PURPOSE OF REVIEW: Obesity is associated with cardiovascular (CV) conditions, including but not limited to atherosclerotic disease, heart failure, and atrial fibrillation. Despite this, the impact of intentional weight loss on CV outcomes for persons with obesity and established CV conditions remains poorly studied. New and emerging pharmacologic therapies for weight loss primarily targeting the incretin/nutrient sensing axes induce substantial and sustained weight loss. The glucagon-like-peptide 1 receptor agonists (GLP-1 RA) liraglutide and semaglutide have US FDA approval for the treatment of obesity, and the application for an obesity indication for the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide is presently under FDA review...
March 2024: Current Cardiology Reports
https://read.qxmd.com/read/38551614/cardiogenic-shock-diagnosis-and-management-in-general-intensive-care-a-nationwide-survey
#25
JOURNAL ARTICLE
Costanza N Colombo, Guido Tavazzi, Michele Zanetti, Francesca Dore, Stefano Finazzi
BACKGROUND: The epidemiology of cardiogenic shock has evolved over the years: in the last decades an increasing prevalence of cardiogenic shock related to acute decompensated heart failure was observed. Therefore, treatment bundles should be updated according to the underlying pathophysiology. No data exist regarding the diagnostic/therapeutic strategies in general intensive care units. METHODS: A 27-questions survey was spread through the GiViTi (Italian Group for the Evaluation of Interventions in Intensive Care Medicine)...
March 29, 2024: Minerva Anestesiologica
https://read.qxmd.com/read/38550516/the-arrhythmic-presentation-of-peripartum-cardiomyopathy-case-series-and-critical-review-of-the-literature
#26
JOURNAL ARTICLE
Giovanni Peretto, Emanuele Micaglio, Giuseppe Ciconte, Marianna Maia, Martina Luzzi, Marianna Cariello, Adele Gabriella Rosa Bonfanti, Davide Lazzeroni, Luigi Anastasia, Paolo Cavoretto, Alaide Chieffo, Paolo Della Bella, Carlo Pappone
Peripartum Cardiomyopathy (PPCM) is a polymorphic myocardial disease occurring late during pregnancy or early after delivery. While reduced systolic function and heart failure (HF) symptoms have been widely described, there is still a lack of reports about the arrhythmic manifestations of the disease. Most importantly, a broad range of unidentified pre-existing conditions, which may be missed by general practitioners and gynecologists, must be considered in differential diagnosis. The issue is relevant since some arrhythmias are associated to sudden cardiac death occurring in young patients, and the overall risk does not cease during the early postpartum period...
2024: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/38546848/inflammation-in-heart-failure-pathophysiology-and-therapeutic-strategies
#27
REVIEW
Jacinthe Boulet, Vikas S Sridhar, Nadia Bouabdallaoui, Jean-Claude Tardif, Michel White
A role for inflammation in the development and progression of heart failure (HF) has been proposed for decades. Multiple studies have demonstrated the potential involvement of several groups of cytokines and chemokines in acute and chronic HF, though targeting these pathways in early therapeutic trials have produced mixed results. These studies served to highlight the complexity and nuances of how pro-inflammatory pathways contribute to the pathogenesis of HF. More recent investigations have highlighted how inflammation may play distinct roles based on HF syndrome phenotypes, findings that may guide the development of novel therapies...
March 28, 2024: Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.]
https://read.qxmd.com/read/38545340/healthcare-needs-in-elderly-patients-with-chronic-heart-failure-in-view-of-a-personalized-blended-collaborative-care-intervention-a-cross-sectional-study
#28
JOURNAL ARTICLE
Sara Gostoli, Francesco Bernardini, Regina Subach, Petra Engelmann, Tiny Jaarsma, Frida Andréasson, Sanne Rasmussen, Trine Thilsing, Natasja Eilerskov, Barbara Bordoni, Diego Della Riva, Stefano Urbinati, Sebastian Kohlmann, Chiara Rafanelli
INTRODUCTION: Few studies explored healthcare needs of elderly heart failure (HF) patients with comorbidities in view of a personalized intervention conducted by Care Managers (CM) in the framework of Blended Collaborative Care (BCC). The aims of the present study were to: (1) identify perceived healthcare needs/preferences in elderly patients with HF prior to a CM intervention; (2) investigate possible associations between healthcare needs/preferences, sociodemographic variables (age; sex) and number of comorbidities...
2024: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/38537948/central-sleep-apnoea-not-just-one-phenotype
#29
REVIEW
Winfried Randerath, Sébastien Baillieul, Renaud Tamisier
Recent scientific findings in the field of sleep disordered breathing have characterised a variety of phenotypes in obstructive sleep apnoea. These findings have prompted investigations aiming to achieve a more precise differentiation and description of the entities of central sleep apnoea (CSA). There is increasing evidence for the heterogeneity of CSA in terms of underlying aetiology, pathophysiological concepts, treatment response and outcome. Assigning patients to these phenotypes allows for the selection of individualised therapies...
January 31, 2024: European Respiratory Review: An Official Journal of the European Respiratory Society
https://read.qxmd.com/read/38537919/sacubitril-valsartan-related-hypotension-in-patients-with-heart-failure-and-preserved-or-mildly-reduced-ejection-fraction
#30
JOURNAL ARTICLE
Alberto Foà, Muthiah Vaduganathan, Brian L Claggett, Maria A Pabon, Henri Lu, Marc A Pfeffer, Milton Packer, Orly Vardeny, Jean L Rouleau, Martin Lefkowitz, Robert J Mentz, Pardeep S Jhund, Akshay S Desai, John Jv McMurray, Scott D Solomon
BACKGROUND: Hypotension is a potential adverse effect of sacubitril/valsartan, but there are limited data regarding the predictors and implications of treatment-related hypotension in HFmrEF and HFpEF. OBJECTIVES: We investigated predictors of treatment-associated hypotension, clinical outcomes after hypotension, and the relationship between LVEF and incidence of hypotension in the PARAGON-HF trial. METHODS: PARAGON-HF randomized patients with chronic HF (≥45%) to sacubitril/valsartan or valsartan...
March 13, 2024: Journal of the American College of Cardiology
https://read.qxmd.com/read/38530599/how-well-do-ed-physician-practices-align-with-the-caep-acute-atrial-fibrillation-checklist-for-stroke-prevention-and-disposition
#31
JOURNAL ARTICLE
Samara Adler, Amanda M S Mattice, Debra Eagles, Krishan Yadav, Sean Hui, Althaf Azward, Nikesh Pandey, Ian Stiell
OBJECTIVES: Acute atrial fibrillation (AF)/flutter (AFL) is a common emergency department (ED) presentation. In 2021, an updated version of CAEP's Acute AF/AFL Best Practices Checklist was published, seeking to guide management. We assessed the alignment with and safety of application of the Checklist, regarding stroke prevention and disposition. METHODS: This health records review included adults presenting to two tertiary care academic EDs between January and August 2022 with a diagnosis of acute AF/AFL...
March 26, 2024: CJEM
https://read.qxmd.com/read/38527048/the-relationship-between-a-series-of-inflammatory-markers-on-the-risk-of-heart-failure-in-different-gender-groups-analysis-from-nhanes-2015-2018
#32
JOURNAL ARTICLE
Ting Cheng, Dongdong Yu, Xingying Qiu, Wenwei OuYang, Geng Li, Li Zhou, Zehuai Wen
BACKGROUND: A better understanding of the level-grade inflammation for the development and worsening of heart failure (HF) in different gender groups is an unmet need. We performed an updated analysis on the impact of a series of systemic inflammation markers on HF. METHODS: This compensatory cross-sectional study enrolled participants from the National Health and Nutrition Examination Survey (NHANES) 2015-2018. HF was based on the self-reported questions. Univariate and multivariate logistic regression were used to investigate the association between systemic immune-inflammation index (SII), high sensitivity C-reactive protein (hs-CRP), lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and HF...
2024: PloS One
https://read.qxmd.com/read/38521534/prognostic-factors-and-prediction-models-for-hospitalisation-and-all-cause-mortality-in-adults-presenting-to-primary-care-with-a-lower-respiratory-tract-infection-a-systematic-review
#33
JOURNAL ARTICLE
Merijn H Rijk, Tamara N Platteel, Teun M C van den Berg, Geert-Jan Geersing, Paul Little, Frans H Rutten, Maarten van Smeden, Roderick P Venekamp
OBJECTIVE: To identify and synthesise relevant existing prognostic factors (PF) and prediction models (PM) for hospitalisation and all-cause mortality within 90 days in primary care patients with acute lower respiratory tract infections (LRTI). DESIGN: Systematic review. METHODS: Systematic searches of MEDLINE, Embase and the Cochrane Library were performed. All PF and PM studies on the risk of hospitalisation or all-cause mortality within 90 days in adult primary care LRTI patients were included...
March 23, 2024: BMJ Open
https://read.qxmd.com/read/38520434/mortality-benefit-among-primary-prevention-implantable-cardioverter-defibrillator-recipients-on-contemporary-heart%C3%A2-failure-treatment
#34
JOURNAL ARTICLE
Aamir Ahmed, Angelo Auricchio, Suneet Mittal, Robert A Pickett, Bruce L Wilkoff, Luke D Jacobsen, Anne K Marti, Reece W Holbrook, Dana M Soderlund, Anne B Curtis
BACKGROUND: Past clinical trials have shown the benefit of implantable cardioverter-defibrillators (ICDs) for reducing sudden cardiac death in at-risk patients. However, heart failure management and ICD technology have changed since these trials were first published. An updated assessment of ICD mortality benefit is needed. OBJECTIVES: The purpose of this study was to compare mortality rates between patients with a primary prevention (PP) indication for an ICD who did or did not receive an ICD using a contemporary, real-world data set...
February 24, 2024: JACC. Clinical Electrophysiology
https://read.qxmd.com/read/38519808/efficacy-of-intravenous-iron-in-patients-with-heart-failure-with-reduced-ejection-fraction-and-iron-deficiency-a-systematic-review-and-meta-analysis-of-randomized-control-trials
#35
Andrew Sephien, Denisse Camille Dayto, Tea Reljic, Xavier Prida, Joanna M Joly, Matthew Tavares, Jason N Katz, Ambuj Kumar
BACKGROUND: The European Society of Cardiology (ESC) provided a focused update to the 2021 Guideline for the Management of Heart Failure, now providing a 1A recommendation for intravenous iron in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency (ID). However, the findings from randomized controlled trials (RCT) are mixed. This systematic review of RCTs aims to provide an update and synthesize the evidence addressing the association of intravenous iron with patient-based outcomes in patients with HFrEF and ID...
March 22, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38515760/crosstalk-between-ubiquitin-ligases-and-ncrnas-drives-cardiovascular-disease-progression
#36
REVIEW
Jia-Rui You, Zeng-Jin Wen, Jia-Wei Tian, Xiao-Bing Lv, Rong Li, Shu-Ping Li, Hui Xin, Pei-Feng Li, Yin-Feng Zhang, Rui Zhang
Cardiovascular diseases (CVDs) are multifactorial chronic diseases and have the highest rates of morbidity and mortality worldwide. The ubiquitin-proteasome system (UPS) plays a crucial role in posttranslational modification and quality control of proteins, maintaining intracellular homeostasis via degradation of misfolded, short-lived, or nonfunctional regulatory proteins. Noncoding RNAs (ncRNAs, such as microRNAs, long noncoding RNAs, circular RNAs and small interfering RNAs) serve as epigenetic factors and directly or indirectly participate in various physiological and pathological processes...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38514585/future-perspectives-of-pulmonary-arterial-hypertension-a-review-of-novel-pipeline-treatments-and-indications
#37
REVIEW
Maria Eugenia Novara, Enrica Di Martino, Brandon Stephens, Mary Nayrouz, Patrizio Vitulo, Anna Carollo, Alessio Provenzani
Pulmonary arterial hypertension is characterized by elevated blood pressure and pathological changes in the pulmonary arterioles, leading to the development of right-heart failure and potentially fatal outcomes if left untreated. This review aims to provide an overview of novel drugs or formulations and new drug indications for pulmonary arterial hypertension that are currently in phases II-III of randomized controlled trials, and describe the rationale for the use of these targeted therapies, as well as their efficacy, safety profile, and impact on quality of life and survival...
March 22, 2024: Drugs in R&D
https://read.qxmd.com/read/38506359/-the-impact-of-regulation-and-central-management-on-patient-safety-in-israel
#38
JOURNAL ARTICLE
Yaron Niv, Yossi Tal
An adverse event is defined as an unwanted and unexpected occurrence in a medical process that may end in harm to the patient. In the USA the number of deaths due to failures reaches 253,000 per year. In Israel, over 10,000 deaths occur per year due to errors in the medical treatment of hospitalized patients, the third most common cause of death after heart disease and cancer. The main cause of failures in medical diagnosis and treatment is the complexity of the medical profession. A large number of caregivers in different medical disciplines are needed to treat one patient, therefore there are many errors, especially regarding communication between therapists...
March 2024: Harefuah
https://read.qxmd.com/read/38456601/sglt2-inhibitors-from-glucose-lowering-to-cardiovascular-benefits
#39
JOURNAL ARTICLE
Alberto Preda, Fabrizio Montecucco, Federico Carbone, Giovanni G Camici, Thomas F Lüscher, Simon Kraler, Luca Liberale
An increasing number of individuals is at high risk of type 2 diabetes (T2D) and its cardiovascular complications, including heart failure (HF), chronic kidney disease (CKD), and premature death. The sodium-glucose cotransporter-2 (SGLT2) protein sits in the proximal tubule of human nephrons to regulate glucose reabsorption, and its inhibition by gliflozins represents the cornerstone of contemporary T2D and HF management. Herein, we aim to provide an updated view on the pleiotropy of gliflozins, provide mechanistic insights and delineate related cardiovascular (CV) benefits...
March 8, 2024: Cardiovascular Research
https://read.qxmd.com/read/38453571/acute-heart-failure-an-efim-guideline-critical-appraisal-and-adaptation-for-internists
#40
JOURNAL ARTICLE
Valentin A Kokorin, Alvaro González-Franco, Antonio Cittadini, Oskars Kalejs, Vera N Larina, Alberto M Marra, Francisco J Medrano, Zdenek Monhart, Laura Morbidoni, Joana Pimenta, Wiktoria Lesniak
BACKGROUND: Over the past two decades, several studies have been conducted that have tried to answer questions on management of patients with acute heart failure (AHF) in terms of diagnosis and treatment. Updated international clinical practice guidelines (CPGs) have endorsed the findings of these studies. The aim of this document was to adapt recommendations of existing guidelines to help internists make decisions about specific and complex scenarios related to AHF. METHODS: The adaptation procedure was to identify firstly unresolved clinical problems in patients with AHF in accordance with the PICO (Population, Intervention, Comparison and Outcomes) process, then conduct a critical assessment of existing CPGs and choose recommendations that are most applicable to these specific scenarios...
March 6, 2024: European Journal of Internal Medicine
keyword
keyword
110951
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.